Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6675MR)

This product GTTS-WQ6675MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6675MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3878MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ15265MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ15206MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ14760MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ15023MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ3477MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ13492MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ2445MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW